Program

769
513
90
82
82
33
26
15
13
11
10
10
9
4
2

Journal Year Published

2
82
161
316
323
373
114
57
46
43
32
16
7
3
2
1
1
2
1
1

Author

163
155
118
114
109
109
103
102
98
74
70
69
62
50
50
38
37
35
31
30

Category

295
289
273
86
82
55
21
18
15
14
2
2

Keyword

1154
568
515
344
325
290
204
177
154
142
120
106
106
102
93
92
89
80
76
76

Journal

43
43
41
28
23
20
17
17
15
14
13
13
13
12
12
11
11
11
11
11

NCATS Publications

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.


Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Sánchez-Rivera FJ, Subbaraj L, Martinez B, Bronson RT, Prigge JR, Schmidt EE, Thomas C, Goparaju C, Davies A, Dolgalev I, Heguy A, Allaj V, Poirier JT, Moreira AL, Rudin CM, Pass HI, Vander Heiden MG, Jacks T, Papagiannakopoulos T


Nat. Med. , (23), 1362-1368, 2017.

Article Pubmed
Sample image from publication page

Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer.


Sayin VI, LeBoeuf SE, Singh SX, Davidson SM, Biancur D, Guzelhan BS, Alvarez SW, Wu WL, Karakousi TR, Zavitsanou AM, Ubriaco J, Muir A, Karagiannis D, Morris P, Thomas C, Possemato R, Vander Heiden MG, Papagiannakopoulos T


Elife , (6), 2017.

Article Pubmed
Sample image from publication page

Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.


Venkatesh HS, Tam LT, Woo PJ, Lennon J, Nagaraja S, Gillespie SM, Ni J, Duveau D, Morris P, Zhao J, Thomas C, Monje M


Nature , (549), 533-537, 2017.

Article Pubmed
Sample image from publication page

Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism.


Krishnan V, Ma YL, Chen C, Thorne N, Bullock H, Tawa G, Javella-Cauley C, Chu S, Li W, Kohn W, Adrian MD, Benson C, Liu L, Sato M, Zheng W, Pilon A, Yang N, Bryant HU


Br. J. Pharmacol. , 2017.

Article Pubmed
Sample image from publication page